BASEBALL - 2017 Lineup?

3,382 Views | 8 Replies | Last: 7 yr ago by BurnetAggie99
heddy Lamarr
How long do you want to ignore this user?
heddy Lamarr
How long do you want to ignore this user?
AG
1B - ??
2B - Homan
SS - Janca
3B - Davis

CF - Choruby
LF - Pennington
RF - ??

C - Bedford
mdanyc03
How long do you want to ignore this user?
AG
Jimmerson and Coll Stanley have a good chance to start.
mdanyc03
How long do you want to ignore this user?
AG
Hunter Coleman or lichty will start at catcher.
dirkjones
How long do you want to ignore this user?
AG
Tristan Metten will probably work his way into the lineup somewhere. Currently batting .375 for the bombers in 17 games with 0 errors.
jpennington
How long do you want to ignore this user?
quote:
1B - ??
2B - Homan
SS - Janca
3B - Davis

CF - Choruby
LF - Pennington
RF - ??

C - Bedford
My guess is that Stanley will play first and either Metten or Janca will play third with the other either at second. Makes sense to leave Homan at short. Davis should play right since he has the slightly stronger arm than Pennington who will most likely be in left. Jimerson and Kopetsky will be in the outfield mix or will be part of the DH rotation.
Foxo
How long do you want to ignore this user?
AG
Will Kopetsky be back?

Metten has no errors but he has mostly played DH and OF. I wonder why?
deh40
How long do you want to ignore this user?
AG
Doubt that Bedford is the starting catcher.
jpennington
How long do you want to ignore this user?
I'm pretty certain Kopetsky has one year remaining of eligibility and will be healthy again. I don't know the other catcher candidates. Bedford has some pop. He was a very good hitter in high school. Limited AB's in college makes it tough to see what he can do on regular basis.
BurnetAggie99
How long do you want to ignore this user?
Kopetsky has a chance to be a pretty good pitcher and good possibility that he's a two way player if he can handle it.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.